What it does
ArxTherapeutics is a Europe-based biotech developing therapeutic molecular clusters, a new class of small-molecule medicine, led by Ag5, which targets mitochondrial antioxidants in metastatic and brain cancers and sensitises tumours to radiotherapy. A second asset, Au5, targets invasive fungal pathogens. The company holds patents on synthesis and therapeutic applications, with published data in Redox Biology (2024) and Blood (2020). It is raising $190m over five years in tranches of $10m, $80m and $100m to take the lead medicine into the clinic.
